A covalent adduct of DFOB and DOTA separated by a L-lysine residue (DFOB-L-Lys-N6-
DOTA) exhibited remarkable regioselective metal binding, with {1H}-13C NMR spectral …

Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

Therapeutic radiopharmaceuticals are radiolabeled molecules designed to deliver
therapeutic doses of ionizing radiation to specific disease sites (1, 2). Therapeutic doses of …

To develop a radioactive metal complex platform for tumor theranostics, we introduced three
radiopharmaceutical derivatives of 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7-trisacetic acid …

Purpose This study was to design and synthesize a novel bifunctional chelator, named Dar,
primarily validated by conjugating to tumor targeting motifs, labeled with radiometals, and …

Herein, we report the synthesis of three new bifunctional heptadentate metal ion binding
chelates derived from desferrioxamine B (DFO) linked to a tripeptide unit that comprises of a …

Zirconium-89-labeled monoclonal antibodies and other large macromolecules such as
nanoparticles hold great promise as positron emission tomography imaging agents. In …

Radiometals comprise many useful radioactive isotopes of various metallic elements. When
properly harnessed, these have valuable emission properties that can be used for …

New DOTA-based bifunctional prochelators, eg, 1-(1-carboxy-3-carbotertbutoxypropyl)-4, 7,
10-(carbotertbutoxymethyl)-1, 4, 7, 10-tetraazacyclodode-cane (DOTAGA (tBu) 4),(6d) for a …

Use of radiometals in nuclear oncology is a rapidly growing field and encompasses a broad
spectrum of radiotracers for imaging via PET (positron emission tomography) or SPECT …